Skip to content
Menu

Arcutis Biotherapeutics, Inc. ARQT

Full chart Compare
Set alert

Price alert · ARQT

All alert types
27.17 USD -0.44 (-1.59%)

Regular-session close

27.17 0.00 0.00%

After hours · Nov 19, 4:39 PM ET

26.99 Day range 28.09
19.30 52-week range 34.80
YTD
-6.44%
1 year
-2.58%

5D -0.04 (-0.15%)

2727.5028FriMonTueWedThu27.17
Market cap
3.44B
Revenue (ttm)
508.68M
Profit margin
5.88%
EPS (ttm)
0.22
Shares out
126.46M
P/E ratio
123.50
Forward P/E
24.83
YTD return
-6.44%
1-year return
-2.58%
50-day average
27.74
Volume
1.33M
Avg volume
2.63M
Open
27.74
Previous close
27.61
Day's range
26.99 – 28.09
52-week range
19.30 – 34.80
Beta
1.63
Analysts
Strong Buy
Price target
40.38 (+48.6%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
25.40
Enterprise value
3.36B
Price / sales
6.75
Price / book
14.03
Revenue growth
45.10%
Free cash flow
32.62M
Total cash
259.46M
Total debt
123.82M
Return on equity
14.88%
Short % of float
15.31%

Fundamental scorecard

12 of 25 checks passed on ARQT’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ARQT Revenue — quarterly 143.92M
ARQT Net income — quarterly 8.80M
ARQT EPS — quarterly 0.07

Earnings

ARQT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20260.21———
Nov 4, 2026Sep 30, 20260.180.06-0.12-66.67%
Aug 5, 2026Jun 30, 20260.055080.11+0.05+99.71%
May 6, 2026Mar 31, 2026-0.02-0.09-0.07-350.00%
Feb 25, 2026Dec 31, 20250.030.13+0.10+333.33%
Oct 28, 2025Sep 30, 2025-0.100.06+0.16+160.00%

Upgrades / downgrades

ARQT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026TD CowenmainBuyBuy
Oct 19, 2026GuggenheimmainBuyBuy
Oct 15, 2026Cantor Fitzgeraldinit—Overweight
Aug 6, 2026Morgan StanleymainOverweightOverweight
Aug 6, 2026GuggenheimmainBuyBuy
Aug 6, 2026NeedhammainBuyBuy

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
arcutis.com

News

Your note

Sign in to keep a note on ARQT — it syncs with the Stock Master app.

Insider holders

ARQT insider holders
InsiderRelationLatest transactionDateShares held
BURNETT PATRICKOfficerSaleNov 1, 2026116,649
CHAUDHURI BHASKARDirectorStock Award(Grant)Jun 11, 2025917,807
EDWARDS LARRY TODDOfficerSaleMar 1, 2026175,178
HERON PATRICK JDirectorStock Award(Grant)Jun 4, 20268,868,640
MATSUDA MASARUOfficerConversion of Exercise of derivative securityNov 3, 2026111,289
PEETZ CHRISTOPHERDirectorStock Award(Grant)Jul 14, 2026191,815

Institution ownership

ARQT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.15.16%19,171,035520.88MSep 29, 2026
Montanova Capital LLC9.70%12,269,000333.35MSep 29, 2026
Frazier Life Sciences Management, L.P. 7.81%9,874,511268.29MSep 29, 2026
Rubric Capital Management LP6.66%8,421,577228.81MSep 29, 2026
State Street Corporation6.10%7,718,628209.72MSep 29, 2026
Polar Capital Holdings PLC5.21%6,592,116179.11MSep 29, 2026

Fund ownership

ARQT fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.39%6,810,517185.04MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.82%3,564,95796.86MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.39%3,020,20382.06MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.34%2,959,24480.40MSep 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund1.16%1,466,41139.84MSep 29, 2026
Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd.1.10%1,386,23737.66MJun 29, 2026